Compare DexCom, Inc. (DXCM) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs US Bancorp — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while US Bancorp trades at $64.51 (market cap $100.01B). The key difference: US Bancorp is far larger — about 3× DexCom, Inc.'s market cap, and US Bancorp pays a 3.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | USB | |
|---|---|---|
Market Cap | $33.08B | $100.01B |
Sector | Health | Financials |
52-Week High | $89.53 | $64.47 |
52-Week Low | $54.84 | $45.28 |
Enterprise Value | $32.53B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
U.S. Bancorp (USB) trades at $63.94, up 0.2% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $70.27. The stock shows strong fundamentals with a P/E of 12.76, net income margin of 27.61%, and three consecutive quarterly EPS beats. Recent news highlights institutional buying and upbeat Q2 2026 results, though RSI levels suggest potential overbought conditions near-term.
Outlook is positive with earnings growth and dividend stability, but risks include interest rate sensitivity and competitive pressures. Upside potential exists if the company maintains its profit trajectory, supported by analyst buy ratings. Investors should monitor debt levels and economic shifts that could impact banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
